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Abstract Avascular or aseptic necrosis is a well-defined en-
tity leading to the degradation of cellular elements of the bone.
The pathogenesis of osteonecrosis (ON) is still unknown.
There are two main types of ON: traumatic or non-
traumatic. Several clinical entities could associate with ON,
systemic diseases, environmental factors, pregnancy, systemic
autoimmune or rheumatic diseases, thrombophilia, corticoste-
roid therapy, cytotoxic dugs, infections, metabolic and hema-
tologic diseases, etc. Corticosteroids (CS) are still the most
frequently used therapeutic options in the early phase and
during flares of these diseases. Inflammatory cytokines and
antibodies have been described to participate in the pathogen-
esis of ON. The infiltrative disorders of the bone marrow
could also contribute to the development of ON. Hereby, we
describe a female patient with NHL followed by SLE in
whom ON has developed at least in two localisations. Lupus
flare, long-termCS therapy, lymphoma relapse or the presence
of antiphospholipid antibodies were excluded. Although the
bi-localised ON could be contributed to immunologic factors
or trauma, the exact aetiology in this case could not be
elucidated.
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Avascular or aseptic necrosis is a well-defined entity leading
to the degradation of cellular elements of the bone. The
pathogenesis of osteonecrosis (ON) is still unknown. There
are twomain types of ON: traumatic or non-traumatic. Several
clinical entities could associate with ON, systemic diseases,
environmental factors, pregnancy, systemic autoimmune or
rheumatic diseases, thrombophilia, corticosteroid therapy, cy-
totoxic dugs, infections, metabolic and hematologic diseases,
etc. There are some systemic autoimmune diseases, such as
systemic lupus erythaematosus (SLE), antiphospholipid syn-
drome (APS) and vasculitis which may associate more fre-
quently with ON than others (1). Corticosteroids (CS) are still
the most frequently used therapeutic options in the early phase
and during flares of these diseases (2). Inflammatory cyto-
kines and antibodies have been described to participate in the
pathogenesis of ON. The infiltrative disorders of the bone
marrow could also contribute to the development of ON;
however, in non-Hodgkin’s lymphomas (NHL), no clear as-
sociation with ON have been shown previously (1). Hereby,
we describe a female patient with NHL followed by SLE in
whom ON has developed at least in two localisations. Lupus
flare, long-termCS therapy, lymphoma relapse or the presence
of antiphospholipid antibodies were excluded. Although the
bi-localised ON could be contributed to immunologic factors
or trauma, the exact aetiology in this case could not be
elucidated.
We report a case of a 32-year-old Caucasian woman with
large B cell mediastinal NHL treated with radiotherapy and
autologous bone marrow transplantation. Following the ther-
apy, she got in remission. Later, at the age of 40, she
complained for fever and polyarthritis. The relapse of the
NHL was suspected therefore positron emission tomography
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(PET) was performed with normal result. Besides
polyarthritis, ANA, a-dsDNA, leukopenia and anaemia devel-
oped; SLE was diagnosed. She was treated with short-term
high-dose CS, followed by low-dose CS, only for a 1-year
period (preventing flares), and chloroquine as maintenance
therapy was administered. Brain magnetic resonance imaging
(MRI), which was performed due to migraine, detected few
small, micro-lacunar, ischemic, micro-vascular lesions, which
could be considered as vasculitis. In January 2012, she
complained for severe right hip pain. Aseptic necrosis of the
femur head was verified with MRI. Because of the movement
restriction and persistent pain, a total endoprothesis was im-
planted into the right hip. Histopathology was consistent with
aseptic osteonecrosis without any signs of malignancy either
in the bone cortex or bone marrow spaces. The surgical
intervention was completed with a complex rehabilitation. In
June 2011, severe left shoulder pain developed. The MRI
showed several subchondral lythic and sclerotic spaces with
particular fractures in the head of the humerus, characteristic
findings for aseptic bone necrosis. Both native CT, FDG-PET
and laboratory investigations excluded malignancy, infection
or the reoccurrence of NHL. There were no clinical or labo-
ratory signs indicating relapse of SLE. None of the
antiphospholipid antibodies were detected since disease onset.
Quantiferon tests for tuberculosis were negative. The serum
bone turnover biochemical markers and parathormone, TSH,
and also 25-OH vitamin D level were normal. Dual X-ray
absorptiometry showed mild osteopenia. The patient did not
drink alcohol habitually; there was no evidence for hyperlip-
idaemia or coagulopathy.
Since the patient received high-dose CS only in the early
phase of the disease (SLE) for remission inductions and CS
was gradually tapered then omitted, the treatment could not be
the cause for the aseptic ON. Presently, she is a recipient for
prosthesis of the left shoulder and also for arthroscopy or
synovectomy of the left elbow.
ON is a clinical feature leading to the degradation of bone
marrow and trabecular bone, resulting in the collapse of bone
architecture. Clinically, it is manifested in bone and joint pain,
bone destruction and loss of function, although it could remain
silent for a long time. However, the pain also can develop
rapidly and can be very intensive, especially when caused by
large infarcts of the femoral head. The aseptic, or as a syno-
nym, avascular necrosis may be caused by several factors,
including local trauma or non-traumatic systemic diseases.
The predisposing factors are alcoholism; iatrogenic agents;
pancreatitis; hematologic, metabolic or endocrine disorders;
pregnancy; neoplastic diseases; systemic autoimmune; rheu-
matic diseases; or orthopaedic disorders. Approximately, in
75 % of the cases, ON starts between the ages of 30 and
60 years. The frequency of avascular necrosis in SLE ranges
from 3 to 30 %; however, a higher frequency (40 %) was
reported in children and young patients with lupus (1).
CS are reported as major risk factors for development of
ON in SLE, where steroids are usually the most frequently
applied treatment options in the early phase or flares of the
disease. ON occurs mainly in SLE patients who are treated
with CS and is extremely rare among those who have never
received CS (2, 3). However, another retrospective study has
shown no relationship between the risk of ON development
and the total dose, duration of steroid therapy and disease
activity (4). However, vasospasm, cushingoid feature, vascu-
litis, smoking, pre-eclampsia and the presence of lupus anti-
coagulant are suspected to be associated with increased risk of
ON (4).
SLE is often associated with APS (5). In our case, the
patient had no presence of antiphospholipid antibodies [anti-
cardiolipin antibody (aCL), lupus anticoagulant and anti-β2-
glycoprotein-I]. There are some case reports and studies de-
scribing the strong association between primary and second-
ary APS and ON (6, 7). However, no difference in the prev-
alence of aCL in patients with or without ON were found
previously (8, 9). A clearly increased risk for NHL has been
described in patients with SLE as compared to those in the
general population. It has still remained unclear to what extent
the association with NHL is mediated by innate versus exog-
enous factors (10, 11). Interestingly, diffuse, large B cell
lymphoma was the first disease in our case preceding lupus.
Therefore, paraneoplastic syndrome had to be accounted,
although lymphoma was confirmed being in remission when
SLE developed. Primary or metastatic bone cancer was ex-
cluded in our case and bone turnover biomarkers were normal.
In myeloma multiplex (MM), osteoclast activation and osteo-
blast inhibition have been described (12). Myeloma cells lead
to an imbalance in the receptor activator of nuclear factor-
kappa B/receptor activator of nuclear factor-kappa B ligand
(RANK/RANK-L)-system in the tumour microenvironment,
such as the receptor activator of nuclear factor-kappa B ligand/
osteoprotegerin (RANK-L/OPG) ratio is essential for normal
bone turnover. Myeloma cells induce RANK-L expression
and decrease OPG secretion by osteoblasts and stromal cells
(13, 14). There are other pathways of MM in the development
of ON, as myeloma cells produce and shed syndecan (CD
138) that binds to the heparin-binding domain of OPG and
mediates its internalisation and lysosomal degradation by
myeloma cells. Other cytokines, as MIP-1α and MIP-1β
enhance RANK-L expression in stromal cells. MIP-1α pro-
motes growth, survival and migration of myeloma cells (15).
There are two basic and common cytokines, interleukin (IL)-6
and IL-11, which are predominantly produced by stromal
cells, as well as inflammatory cells involved in SLE (16).
Both the upregulation of IL-6 secretion through cell-to-cell
contact and the downregulation of OPG result in increased
osteoclast activation and a consequent bone resorption. Less
defined in lupus, but the IL-3, hepatocyte growth factor
(HGF), SDF-1α and its receptor CXCR4 are expressed on
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osteoclast precursors, which all increase osteoclast motility
and bone-resorpting activity. Other similar ON-provoking
factors, as MMP-1 and MMP-2, urokinase plasminogen acti-
vator and HGF, are recognised both inMM and lupus (17, 18).
Presumably, these factors may lead to avascular necrosis of
the bone in NHL. Bernbeck et al. described bone marrow
oedema and aseptic necrosis in children and adolescent with
acute lymphoblastic leukaemia or NHL treated with hyper-
baric oxygen therapy, whereas the ON was contributed to the
treatment rather than the haematologic disease (19). In MM,
there are some promising therapeutic options, as antibodies to
MIP-1α and MIP-1β or DKK-1 gene produced protein which
could be also effective in lupus-associated ON (20). Anti-IL-6
and anti-IL-3 may be common therapeutic options in lupus
and associated ON (16, 21), while shared therapeutic targets
between lupus and myeloma, such as proteasome inhibitors
also can be considered in these patients (22, 23). We believe
that the development of ON in our patient was due to a
systemic immune activation, pro-inflammatory cytokine se-
cretion and presumably altered RANK/RANKL system.
Targeting pro-inflammatory cytokines and anti-resorptive
therapy can be beneficial in lupus patients with ON.
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